MASI

MASI catalogs interactions between human microbiota and active substances—pharmaceuticals, dietary components, herbal compounds, probiotics, and environmental agents—to support research on microbiota-mediated modulation of bioavailability, bioactivity, toxicity, and disease associations.

Key Features:

• Extensive interaction cataloging: MASI contains detailed information on how gut microbiota alter the bioavailability, bioactivity, and toxicity of approximately 1,051 pharmaceuticals, 103 dietary substances, 119 herbal compounds, 46 probiotics, and 142 environmental agents, and how these substances affect microbiota composition and function.
• Microbiota species coverage: The database includes interactions involving 806 microbiota species, linked to 56 diseases and documenting 784 microbiota–disease associations.
• Interaction data counts: MASI records over 11,215 bacteria–pharmaceutical, 914 bacteria–herbal, 309 bacteria–dietary, and 753 bacteria–environmental substance interactions.
• Human microbiota abundance profiles: MASI contains abundance profiles for 259 bacterial species across 3,465 patients and 5,334 healthy individuals.

Scientific Applications:

• Microbiota-guided precision medicine: Enables investigation of how microbiota-mediated drug modification affects therapeutic outcomes and personalized treatment strategies.
• Pharmaceutical development and pharmacology: Provides interaction data relevant to drug bioavailability, bioactivity, and toxicity mediated by gut bacteria.
• Nutrition, herbal, and environmental exposure studies: Supports analysis of dietary components, herbal compounds, probiotics, and environmental agents on microbiota composition and function.
• Clinical pharmacy and disease research: Facilitates study of microbiota–disease associations and development of microbiota-modulating strategies for disease prevention and treatment.

Methodology:

Integration of curated data on microbiota-mediated modification of active substances and reciprocal substance-induced microbiota changes together with human gut bacterial abundance profiles.